Gavi board keeps 500M immunizations target despite funding gap
Gavi's Board concluded a two-day meeting on 2 July 2026 and locked in ambitious Gavi 6.0 immunizations targets for 2026–2030: reaching 500 million more children, preventing 8–9 million deaths, and advancing country sovereignty, fragile-context support, and African vaccine manufacturing despite a tight funding environment.
The Vaccine Alliance's Geneva decisions shape how national governments—not external partners—will lead vaccination programs while global health security risks rise. For readers who follow global health finance alongside Fintech & Crypto Alerts, the package pairs innovative liquidity with digital payment mandates for frontline workers.
Key Takeaways
- Gavi 6.0 retains targets to vaccinate 500 million additional children and prevent 8–9 million deaths through 2030.
- New country vaccine budget and co-financing policies prioritize low-income, fragile, and humanitarian settings.
- Digital payments become the default mechanism for paying health workers in immunization campaigns.
- Fragile settings receive up to US$ 100 million in co-financing waivers and a US$ 250 million Gavi Resilience Mechanism.
- An additional US$ 189 million boosts Africa's vaccine manufacturing via the AVMA program beyond its US$ 1 billion base.
What Did Gavi's Board Decide on Immunizations?
Meeting in Geneva on 2 July 2026, the Board of Gavi, the Vaccine Alliance approved decisions governing its 2026–2030 strategy, known as Gavi 6.0. Despite what Gavi described as a financially constrained environment, members agreed to maintain targets to reach 500 million more children, prevent an additional 8–9 million deaths, support a further 10% reduction in under-five mortality, and unlock more than US$ 100 billion in economic benefits.
The Board also reviewed outcomes from the 2021–2025 strategic period. Gavi exceeded most targets on children reached, vaccine introductions, and healthy markets despite COVID-19 disruption. However, reducing zero-dose children and ensuring geographic equity in access remained off track—gaps that now sit at the center of the new plan.
Why Does Country Sovereignty Matter for Gavi 6.0?
A major theme of the meeting was shifting power to national governments. The Board passed new policies on country vaccine budgets and co-financing for preventive vaccination campaigns, tailored to deliver the highest support where need is greatest.
Gavi CEO Dr. Sania Nishtar said the decisions reaffirm country ownership and support for the most vulnerable at the heart of the Alliance's operating model through the Gavi Leap reform program. Campaigns will prioritize digital payments for health workers where feasible, a move Nishtar said would eliminate misuse and ensure fair, timely pay based on her experience as a minister.
Board Chair Rt. Hon. Helen Clark said sustained commitment to immunisation shows what is possible, but the world must keep prioritizing vaccines as a cost-effective investment in health, security, and prosperity amid rising outbreak and pandemic risks.
How Will Gavi Support Fragile and Humanitarian Settings?
The Board agreed use cases for a new approach to fragile and humanitarian contexts during Gavi 6.0. This includes up to US$ 100 million for potential waivers of co-financing requirements for eligible countries.
Members also approved a Gavi Resilience Mechanism—a dedicated US$ 250 million fund for unforeseen needs in these settings, including disease outbreaks not covered by existing stockpile mechanisms. Capital FM Kenya reported the package responds to a volatile global health landscape where reaching underserved communities remains a central priority.
What Funding and Manufacturing Moves Back the Plan?
To sustain programs amid funding uncertainty, the Board extended the European Investment Bank Frontloading Facility through end-2026. Gavi may draw up to €500 million from the facility, backed by donor pledges, to ensure continuity of core activities.
On manufacturing, the Board approved an additional US$ 189 million for the African Vaccine Manufacturing Accelerator beyond its existing US$ 1 billion program. US$ 139 million will buy African-made vaccines, supplementing procurement budgets, while US$ 50 million supports ecosystem work with the Africa CDC, African Medicines Agency, and WHO.
Leadership changes include Dr. Mekdes Daba as Vice-Chair and Governance Committee Chair, Henry Gonzalez as an unaffiliated Board member and Investment Committee Chair, and Dr. Rana Hajjeh as Chair of the Independent Review Committee.